At the 2019 Congress of the European Society of Medical Oncology, PARP inhibitors continued their victory march. With the success of the PAOLA-1 trial, reported in Friday's plenary session, as well as the PRIMA and VELIA/GOG-3005 trials, "we've got new front-line data that really introduces a paradigm shift into the way we're going to treat ovarian cancer in the coming years," Jonathan Ledermann, professor of medical oncology at University College London, told the audience at a session on new options on ovarian cancer.
BARCELONA, Spain – At the 2019 Conference of the European Society of Medical Oncology (ESMO), results from the ClarIDHy and FIGHT-202 trials, both testing drugs for the treatment of cholangiocarcinoma, illustrated how molecular medicine can bring new treatments to rare tumors.
BARCELONA, Spain – Sunday's Presidential Symposium at the 2019 Congress of the European Society of Medical Oncology was devoted to breast cancer studies, and two of those studies – MONARCH-2 and MONALEESA-3 – reported an overall survival (OS) benefit of combining a CDK4/6 inhibitor with endocrine therapy Faslodex (fulvestrant) in metastatic hormone receptor-positive (HR+) breast cancer in several different settings.
Despite the fact that antidepressants are taken by more than 10% of the U.S. population, large randomized controlled trials have found little evidence that they are beneficial. However, anecdotal evidence suggests that some patients benefit strongly.
BARCELONA, Spain – This year's theme at the European Society for Medical Oncology's (ESMO) 2019 annual meeting is "translating science into better patient care."
The leucine-repeat rich kinase 2 (Lrrk2) gets most of its attention in the context of Parkinson's disease (PD). Variants in Lrrk2 are a major cause of familial PD (though familial PD makes up only a small fraction of overall PD cases).
Looking at human tissues has given British researchers a new window into the relationship between adipose tissue and disease cardiovascular disease risk.
Scientists at the University of Freiburg have shown that antibody-based prophylactic treatment after bone marrow transplant (BMT) could prevent infections without reducing the diversity of the gut microbiome. BMT is a cure for a number of blood cancers, but it has a very high complication and death rate itself.
In the world of cancer genomics, mutational hotspots and cancer drivers are used somewhat interchangeably. "It was common knowledge... that if you see a site [mutated] in many cancers, that site is a driver," Gad Getz told BioWorld. But Getz, who is director of the Cancer Genome Computational Analysis Group at the Broad Institute of MIT and Harvard, and his team argue that the conventional wisdom is incorrect.
CAR T cells engineered to target fibroblast activating protein (FAP) could reverse cardiac fibrosis and restore cardiac function in mice, researchers have reported in the Sept. 12, 2019, issue of Nature.
